Benzinga · Sep 28, 2026
Truist Securities Reiterates Buy on Xencor, Raises Price Target to $29
Truist Securities analyst Gregory Renza reiterates Xencor (NASDAQ:XNCR) with a Buy and raises the price target from $27 to $29.
XN
NASDAQ · XNCR
Xencor, Inc.
Healthcare · Biotechnology
$25.63
Down-$1.27 (-4.96%)
Updated Oct 6, 2026, 10:10 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.22B
- P/E ratio
- -7.12
- Dividend yield
- 0.00%
- 52-week range
- $10.38 – $30.61
- Volume
- 1.28M
- Avg. volume
- 1.16M
Price performance · XNCR
XNCR price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
XNCR closed at $25.63 after 20 trading sessions, up 1.18% for the selected period.
- Last close
- $25.63
- Period change
- +1.18%
- Period low
- $23.71
- Period high
- $25.63
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $24.83 | $26.01 | $24.83 | $25.63 | 1.28M |
| Oct 2, 2026 | $25.36 | $25.50 | $24.135 | $24.84 | 1.1M |
| Oct 1, 2026 | $24.57 | $25.275 | $24.375 | $24.77 | 1.09M |
| Sep 30, 2026 | $25.36 | $26.35 | $24.94 | $24.95 | 1.54M |
| Sep 29, 2026 | $25.82 | $25.9836 | $24.605 | $25.00 | 1.62M |
| Sep 28, 2026 | $23.90 | $25.71 | $23.74 | $25.60 | 1.53M |
| Sep 25, 2026 | $24.10 | $24.29 | $23.305 | $23.80 | 1.17M |
| Sep 24, 2026 | $24.16 | $24.692 | $23.69 | $23.88 | 952.64K |
| Sep 23, 2026 | $25.42 | $25.63 | $23.99 | $24.26 | 1.16M |
| Sep 22, 2026 | $25.08 | $25.6996 | $24.86 | $25.16 | 1.22M |
| Sep 21, 2026 | $25.46 | $25.46 | $24.64 | $25.03 | 1.39M |
| Sep 18, 2026 | $24.45 | $25.0228 | $24.1283 | $24.72 | 5.21M |
| Sep 17, 2026 | $24.25 | $24.865 | $23.98 | $24.59 | 1.03M |
| Sep 16, 2026 | $23.87 | $24.11 | $23.64 | $23.71 | 1.23M |
| Sep 15, 2026 | $24.42 | $24.42 | $23.36 | $23.75 | 1.82M |
| Sep 14, 2026 | $24.71 | $24.95 | $24.46 | $24.53 | 858.32K |
| Sep 11, 2026 | $24.72 | $24.84 | $23.9601 | $24.41 | 905.27K |
| Sep 10, 2026 | $24.63 | $24.63 | $23.86 | $24.26 | 1.36M |
| Sep 9, 2026 | $25.12 | $26.18 | $24.85 | $24.94 | 1.18M |
| Sep 8, 2026 | $26.09 | $26.4854 | $24.9284 | $25.33 | 1.24M |
Latest XNCR news
The latest Smart Investors Daily articles mentioning XNCR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
XNCR research
Overview
Company profile and research snapshot.
Company profile
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $27.60
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 28, 2026 | Truist Securities | Buy | — |
| Sep 21, 2026 | B of A Securities | Neutral | — |
| Sep 11, 2026 | Barclays | Overweight | — |
| Sep 3, 2026 | JP Morgan | Neutral | — |
| Sep 1, 2026 | Raymond James | Strong Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 21, 2026
B of A Securities Maintains Neutral on Xencor, Raises Price Target to $26
B of A Securities analyst Alec Stranahan maintains Xencor (NASDAQ:XNCR) with a Neutral and raises the price target from $20 to $26.
Benzinga · Sep 11, 2026
Barclays Maintains Overweight on Xencor, Raises Price Target to $35
Barclays analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $27 to $35.
Benzinga · Sep 3, 2026
JP Morgan Maintains Neutral on Xencor, Raises Price Target to $21
JP Morgan analyst Brian Cheng maintains Xencor (NASDAQ:XNCR) with a Neutral and raises the price target from $14 to $21.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
